An evidence-based review of neuronal cholesterol role in dementia and statins as a pharmacotherapy in reducing risk of dementia
- 29 November 2021
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 21 (12) , 1455-1472
Abstract
: Dementia is a progressive neurodegenerative disorder impairing memory and cognition. Alzheimer’s Disease, followed by vascular dementia - the most typical form. Risk factors for vascular dementia include diabetes, cardiovascular disease, hyperlipidemia. Lipids’ levels are significantly associated with vascular changes in the brain. : The present article reviews the cholesterol metabolism in the brain, which includes: the synthesis, transport, storage, and elimination process. Additionally, it reviews the role of cholesterol in the pathogenesis of dementia and statin as a therapeutic intervention in dementia. In addition to the above, it further reviews evidence in support of as well as against statin therapy in dementia, recent updates of statin pharmacology, and demerits of use of statin pharmacotherapy. : Amyloid-β peptides and intraneuronal neurofibrillary tangles are markers of Alzheimer’s disease. Evidence shows cholesterol modulates the functioning of enzymes associated with Amyloid-β peptide processing and synthesis. Lowering cholesterol using statin may help prevent or delay the progression of dementia. This paper reviews the role of statin in dementia and recommends extensive future studies, including genetic research, to obtain a precise medication approach for patients with dementia.Keywords
This publication has 199 references indexed in Scilit:
- Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer’s diseaseLipids in Health and Disease, 2013
- Comparative Lipidomic Analysis of Mouse and Human Brain with Alzheimer DiseaseJournal of Biological Chemistry, 2012
- Reduction of Brain β-Amyloid (Aβ) by Fluvastatin, a Hydroxymethylglutaryl-CoA Reductase Inhibitor, through Increase in Degradation of Amyloid Precursor Protein C-terminal Fragments (APP-CTFs) and Aβ ClearanceJournal of Biological Chemistry, 2010
- Meta-Analysis of Alzheimer's Disease Risk with Obesity, Diabetes, and Related DisordersBiological Psychiatry, 2010
- Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's diseaseNature Genetics, 2009
- Amyloid β-protein stimulates trafficking of cholesterol and caveolin-1 from the plasma membrane to the Golgi complex in mouse primary astrocytesNeuroscience, 2009
- Structural Studies of the Transmembrane C-Terminal Domain of the Amyloid Precursor Protein (APP): Does APP Function as a Cholesterol Sensor?Biochemistry, 2008
- Direct and Potent Regulation of γ-Secretase by Its Lipid MicroenvironmentJournal of Biological Chemistry, 2008
- Cholesterol retention in Alzheimer's brain is responsible for high β- and γ-secretase activities and Aβ productionNeurobiology of Disease, 2008
- Alzheimer's diseaseThe Lancet, 2006